Advanced search
Publication Cover
Biologics: Targets and Therapy Volume 12, 2018 - Issue
Submit an article Journal homepage
77
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Yusuf Yazici1 Rheumatology, New York University, School of Medicine, New York, NY, USA
,
Lin Xie2 Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA, [email protected]
,
Adesuwa Ogbomo2 Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA, [email protected]Correspondence[email protected]
,
Lorie A Ellis3 Real World Value and Evidence, Janssen Scientific Affairs, Titusville, NJ, USA
,
Kavitha Goyal4 Immunology Medical Affairs, Janssen Biotech Incorporated, Horsham, PA, USA
,
Amanda Teeple5 Health Economics and Outcomes Research, Jassen Scientific Affairs, LLC, Horsham, PA, USA
&
Ismail Simsek6 Department of Rheumatology, Guven Hospital, Ankara, Turkey
 show all
Pages 127-134 | Published online: 25 Oct 2018

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Yinong Young-Xu, Richard Melsheimer, Bruno Emond, Patrick Lefebvre, Maral DerSarkissian, Angela Lax, Catherine Nguyen, Rachel H. Bhak, Melody Wu & Iris Lin. (2022) Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627. Current Medical Research and Opinion 38:12, pages 2237-2240.
Read now
Iris Lin, Richard Melsheimer, Rachel H. Bhak, Patrick Lefebvre, Maral DerSarkissian, Bruno Emond, Angela Lax, Catherine Nguyen, Melody Wu & Yinong Young-Xu. (2022) Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Current Medical Research and Opinion 38:4, pages 613-627.
Read now
Timothy Fitzgerald, Richard Melsheimer, Marie-Hélène Lafeuille, Patrick Lefebvre, Laura Morrison, Kimberly Woodruff, Iris Lin & Bruno Emond. (2021) Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab. Biologics: Targets and Therapy 15, pages 1-15.
Read now
Ji-Won Kim, Ju-Yang Jung & Chang-Hee Suh. (2021) Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review. Expert Opinion on Biological Therapy 21:1, pages 57-73.
Read now
Maurizio Benucci & Fabrizio Cantini. (2019) Non-medical switching: save today and pay tomorrow. Journal of Medical Economics 22:11, pages 1160-1161.
Read now

Articles from other publishers (1)

Rosanne W. Meijboom, Helga Gardarsdottir, Toine C. G. Egberts & Thijs J. Giezen. (2021) Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review. BioDrugs 36:1, pages 27-39.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.